Impact of ROS-Dependent Lipid Metabolism on Psoriasis Pathophysiology

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Oct 27

PMID 36292991

Authors

Adam Wronski

Piotr Wojcik

Affiliations

Soon will be listed here.

Abstract

Psoriasis is the most common autoimmune disease, yet its pathophysiology is not fully understood. It is now believed that psoriasis is caused by the increased activation of immune cells, especially Th1 lymphocytes. However, in psoriasis, immune cells interfere with the metabolism of keratinocytes, leading to their increased activation. Therefore, the pathophysiology of psoriasis is currently associated with the overproduction of ROS, which are involved in the activation of immune cells and keratinocytes as well as the modulation of various signaling pathways within them. Nevertheless, ROS modulate the immune system by also boosting the increasing generation of various lipid mediators, such as products of lipid peroxidation as well as endocannabinoids and prostaglandins. In psoriasis, the excessive generation of ROS and lipid mediators is observed in different immune cells, such as granulocytes, dendritic cells, and lymphocytes. All of the above may be activated by ROS and lipid mediators, which leads to inflammation. Nevertheless, ROS and lipid mediators regulate lymphocyte differentiation in favor of Th1 and may also interact directly with keratinocytes, which is also observed in psoriasis. Thus, the analysis of the influence of oxidative stress and its consequences for metabolic changes, including lipidomic ones, in psoriasis may be of diagnostic and therapeutic importance.

Citing Articles

Oxidative Stress and Generalised Pustular Psoriasis: Report of d-ROM Measurements in Nine Cases Including Three of Pustular Psoriasis of Pregnancy.

Tawada C, Ueda Y, Mizutani Y, Zang X, Tanaka K, Iwata H Exp Dermatol. 2025; 34(3):e70076.

PMID: 40062426 PMC: 11891987. DOI: 10.1111/exd.70076.

Limonin Exhibits Anti-Inflammatory Effects by Inhibiting mTORC1 and Mitochondrial Reactive Oxygen Species in Psoriatic-like Skin Inflammation.

Lee S, Lee J, Kim H, Park J, Choi J Antioxidants (Basel). 2025; 13(12.

PMID: 39765869 PMC: 11727202. DOI: 10.3390/antiox13121541.

Therapeutic potential of monomethyl fumarate and aluminum ion combination in alleviating inflammation and oxidative stress in psoriasis.

Han H, Zhang G, Yang Y, Li C, Li X, Zhong L Redox Biol. 2024; 79():103482.

PMID: 39736200 PMC: 11750270. DOI: 10.1016/j.redox.2024.103482.

The Role of Vitamin D3 Deficiency and Colonization of the Oral Mucosa by Yeast-like Fungi in the Pathomechanism of Psoriasis.

Marchlewicz M, Sagan P, Grabowska M, Kiedrowicz M, Kruk J, Gill K J Clin Med. 2024; 13(22).

PMID: 39598018 PMC: 11594318. DOI: 10.3390/jcm13226874.

An Outlook on Platinum-Based Active Ingredients for Dermatologic and Skincare Applications.

Li S, Liu Y, Wu Y, Ren L, Lu Y, Yamaguchi S Nanomaterials (Basel). 2024; 14(15).

PMID: 39120408 PMC: 11314049. DOI: 10.3390/nano14151303.

References

Caslake M, Packard C, Suckling K, Holmes S, Chamberlain P, Macphee C . Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000; 150(2):413-9. DOI: 10.1016/s0021-9150(99)00406-2. View

Prasad C, Davis K, Imrhan V, Juma S, Vijayagopal P . Advanced Glycation End Products and Risks for Chronic Diseases: Intervening Through Lifestyle Modification. Am J Lifestyle Med. 2019; 13(4):384-404. PMC: 6600625. DOI: 10.1177/1559827617708991. View

Goodfield M . Skin lesions in psoriasis. Baillieres Clin Rheumatol. 1994; 8(2):295-316. DOI: 10.1016/s0950-3579(94)80020-0. View

Milne G, Yin H, Hardy K, Davies S, Roberts 2nd L . Isoprostane generation and function. Chem Rev. 2011; 111(10):5973-96. PMC: 3192249. DOI: 10.1021/cr200160h. View

Prinz J, Gross B, Vollmer S, Trommler P, Strobel I, Meurer M . T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol. 1994; 24(3):593-8. DOI: 10.1002/eji.1830240315. View

Ferretti G, Bacchetti T, Campanati A, Simonetti O, Liberati G, Offidani A . Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. Br J Dermatol. 2011; 166(1):204-7. DOI: 10.1111/j.1365-2133.2011.10539.x. View

Shubbar E, Vegfors J, Carlstrom M, Petersson S, Enerback C . Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation. Breast Cancer Res Treat. 2011; 134(1):71-80. DOI: 10.1007/s10549-011-1920-5. View

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

Demerjian M, Man M, Choi E, Brown B, Crumrine D, Chang S . Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol. 2006; 15(3):154-60. DOI: 10.1111/j.1600-0625.2006.00402.x. View

10.

Moussion C, Girard J . Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature. 2011; 479(7374):542-6. DOI: 10.1038/nature10540. View

11.

Barygina V, Becatti M, Soldi G, Prignano F, Lotti T, Nassi P . Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF-α therapy. Redox Rep. 2013; 18(3):100-6. PMC: 6837649. DOI: 10.1179/1351000213Y.0000000045. View

12.

Dwyer K, Deaglio S, Gao W, Friedman D, Strom T, Robson S . CD39 and control of cellular immune responses. Purinergic Signal. 2008; 3(1-2):171-80. PMC: 2096766. DOI: 10.1007/s11302-006-9050-y. View

13.

Vinter H, Iversen L, Steiniche T, Kragballe K, Johansen C . Aldara®-induced skin inflammation: studies of patients with psoriasis. Br J Dermatol. 2014; 172(2):345-53. DOI: 10.1111/bjd.13236. View

14.

Albanesi C, Madonna S, Gisondi P, Girolomoni G . The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. Front Immunol. 2018; 9:1549. PMC: 6043636. DOI: 10.3389/fimmu.2018.01549. View

15.

Fiorentino D, Bond M, Mosmann T . Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989; 170(6):2081-95. PMC: 2189521. DOI: 10.1084/jem.170.6.2081. View

16.

Leitinger N, Huber J, Rizza C, Mechtcheriakova D, Bochkov V, Koshelnick Y . The isoprostane 8-iso-PGF(2alpha) stimulates endothelial cells to bind monocytes: differences from thromboxane-mediated endothelial activation. FASEB J. 2001; 15(7):1254-6. DOI: 10.1096/fj.00-0498fje. View

17.

Romanowska M, Reilly L, Palmer C, Gustafsson M, Foerster J . Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo. PLoS One. 2010; 5(3):e9701. PMC: 2838790. DOI: 10.1371/journal.pone.0009701. View

18.

Gegotek A, Domingues P, Wronski A, Wojcik P, Skrzydlewska E . Proteomic plasma profile of psoriatic patients. J Pharm Biomed Anal. 2018; 155:185-193. DOI: 10.1016/j.jpba.2018.03.068. View

19.

Sorokin A, Domenichiello A, Dey A, Yuan Z, Goyal A, Rose S . Bioactive Lipid Mediator Profiles in Human Psoriasis Skin and Blood. J Invest Dermatol. 2018; 138(7):1518-1528. PMC: 6121727. DOI: 10.1016/j.jid.2018.02.003. View

20.

Walker F, Adamczyk A, Kellerer C, Belge K, Bruck J, Berner T . Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life. Br J Dermatol. 2014; 171(5):1197-205. DOI: 10.1111/bjd.13098. View